Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
Primary Purpose
Melasma
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Revlite Q switched Nd:YAG
Trivantage Q switched Nd: YAG
Sponsored by
About this trial
This is an interventional device feasibility trial for Melasma
Eligibility Criteria
Inclusion Criteria:
- Subjects with Fitzpatrick Skin Type III-VI
- Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.
- Subjects who are over the age of 18 years of age
- The subject is willing and able to comply with study instructions and return to the clinic for required visits.
- The subject's melasma has persisted for greater than 6 months and has failed to respond to conventional treatment with hydroquinone cream or other topical lightening agents.
Exclusion Criteria:
- The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
- The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
- The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy.
- The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy).
- The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
- The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.
- The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present.
- The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
- The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
- The subject has Diabetes Type 1 or 2.
- The subject has a sensitivity to hydroquinone or Retin-A.
- The subject has evidence of a compromised immune system or hepatitis.
- Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks.
- Has a history of keloids or hypertrophic scarring
- Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study
Sites / Locations
- NY Laser and Skin Care
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Revlite Q switched Nd:YAG laser
TriVantage Q switched Nd:YAG laser
Arm Description
Revlite Q switched Nd:YAG laser 1064 nm
TriVantage Q switched Nd:YAG laser 1064nm
Outcomes
Primary Outcome Measures
Changes in Melasma Determined by Physician
The Global Aesthetic Improvement scale was used to determine the amount of improvement. This scale ranges from 1 to 5, where 1 is very much improved, 2 is much improved, 3 is improved, 4 is no change, and 5 is worsened.
Secondary Outcome Measures
Universal Pain Scale for Subject Tolerability
The subject pain tolerability was assessed using the Universal Pain Scale. This scale ranges from 0 (no pain) to 10 (worst pain possible).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01745224
Brief Title
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Terminated
Why Stopped
The study stopped because patient enrollment requirements were not met.
Study Start Date
July 2012 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cynosure, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melasma
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This was a comparative study where the device was used outside of the recommended treatment usage. It was used to assess the Revlite device for feasibility and not health outcomes.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Revlite Q switched Nd:YAG laser
Arm Type
Experimental
Arm Description
Revlite Q switched Nd:YAG laser 1064 nm
Arm Title
TriVantage Q switched Nd:YAG laser
Arm Type
Experimental
Arm Description
TriVantage Q switched Nd:YAG laser 1064nm
Intervention Type
Device
Intervention Name(s)
Revlite Q switched Nd:YAG
Intervention Description
Revlite Q switched Nd:YAG 1064nm
Intervention Type
Device
Intervention Name(s)
Trivantage Q switched Nd: YAG
Intervention Description
Trivantage Q switched Nd: YAG 1064nm
Primary Outcome Measure Information:
Title
Changes in Melasma Determined by Physician
Description
The Global Aesthetic Improvement scale was used to determine the amount of improvement. This scale ranges from 1 to 5, where 1 is very much improved, 2 is much improved, 3 is improved, 4 is no change, and 5 is worsened.
Time Frame
3 months post last treatment
Secondary Outcome Measure Information:
Title
Universal Pain Scale for Subject Tolerability
Description
The subject pain tolerability was assessed using the Universal Pain Scale. This scale ranges from 0 (no pain) to 10 (worst pain possible).
Time Frame
3 months post last treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with Fitzpatrick Skin Type III-VI
Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.
Subjects who are over the age of 18 years of age
The subject is willing and able to comply with study instructions and return to the clinic for required visits.
The subject's melasma has persisted for greater than 6 months and has failed to respond to conventional treatment with hydroquinone cream or other topical lightening agents.
Exclusion Criteria:
The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy.
The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy).
The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.
The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present.
The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
The subject has Diabetes Type 1 or 2.
The subject has a sensitivity to hydroquinone or Retin-A.
The subject has evidence of a compromised immune system or hepatitis.
Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks.
Has a history of keloids or hypertrophic scarring
Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia Krantz
Organizational Affiliation
Cynosure, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
NY Laser and Skin Care
City
New York
State/Province
New York
ZIP/Postal Code
10028
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
We'll reach out to this number within 24 hrs